These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19533830)

  • 1. [Questionable CRP and statin study].
    Røiri P
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1238. PubMed ID: 19533830
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of C-reactive protein on treatment of patients with cardiovascular disease.
    Gortney JS; Sanders RM
    Am J Health Syst Pharm; 2007 Oct; 64(19):2009-16. PubMed ID: 17893410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of statin-associated mortality reduction in COPD.
    Hurst JR; Hagan G; Wedzicha JA
    Chest; 2007 Oct; 132(4):1409; author reply 1409-10. PubMed ID: 17934133
    [No Abstract]   [Full Text] [Related]  

  • 4. [CRP level as risk marker of cardiovascular disease?].
    Thelle DS; Arnesen E
    Tidsskr Nor Laegeforen; 2010 Mar; 130(5):512-4. PubMed ID: 20224622
    [No Abstract]   [Full Text] [Related]  

  • 5. Statin treatment of rheumatoid arthritis: comment on the editorial by Ridker and Solomon.
    Peters MJ; Nurmohamed MT; Kitas GD; Sattar N
    Arthritis Rheum; 2010 Jan; 62(1):302-3. PubMed ID: 20039426
    [No Abstract]   [Full Text] [Related]  

  • 6. More evidence support benefits of statins for low-risk patients. Study adds more fuel to the debate on whether to prescribe statins for patients with low levels of C-reactive protein and LDL cholesterol.
    Duke Med Health News; 2011 May; 17(5):6. PubMed ID: 21766532
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.
    Di Napoli M; Schwaninger M; Cappelli R; Ceccarelli E; Di Gianfilippo G; Donati C; Emsley HC; Forconi S; Hopkins SJ; Masotti L; Muir KW; Paciucci A; Papa F; Roncacci S; Sander D; Sander K; Smith CJ; Stefanini A; Weber D
    Stroke; 2005 Jun; 36(6):1316-29. PubMed ID: 15879341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of C-reactive protein when prescribing a statin.
    Kinlay S
    Curr Atheroscler Rep; 2012 Feb; 14(1):26-32. PubMed ID: 22125118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hs-CRP in cardiovascular risk prediction.
    Am J Manag Care; 2002 Jul; Suppl Symposium Reporter():6, 8. PubMed ID: 12608152
    [No Abstract]   [Full Text] [Related]  

  • 11. Statin therapy dose and risk of new-onset diabetes.
    McEvoy JW
    JAMA; 2011 Sep; 306(12):1325-6; author reply 1326. PubMed ID: 21954475
    [No Abstract]   [Full Text] [Related]  

  • 12. C-reactive protein and cardiovascular diseases--is it ready for primetime?
    Lavie CJ; Milani RV; Verma A; O'Keefe JH
    Am J Med Sci; 2009 Dec; 338(6):486-92. PubMed ID: 20010156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I've heard that statins can can help lower C-reactive proteins (CRP) levels. I'm 65, but I don't take a statin because my cholesterol is low. Should I be concerned about CRP? I have a family history of heart disease.
    Heart Advis; 2011 Feb; 14(2):8. PubMed ID: 22957365
    [No Abstract]   [Full Text] [Related]  

  • 14. C-reactive protein and cardiovascular risk: more fuel to the fire.
    Boekholdt SM; Kastelein JJ
    Lancet; 2010 Jan; 375(9709):95-6. PubMed ID: 20031200
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comment from the lipidologic viewpoint].
    Riesen WF
    Praxis (Bern 1994); 2009 Feb; 98(3):125-7. PubMed ID: 19180437
    [No Abstract]   [Full Text] [Related]  

  • 16. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS; Larsen AI
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive statin therapy--a sea change in cardiovascular prevention.
    Topol EJ
    N Engl J Med; 2004 Apr; 350(15):1562-4. PubMed ID: 15007111
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose statin therapy: benefits and safety in aggressive lipid lowering.
    Toth PP; Davidson MH
    J Fam Pract; 2008 May; 57(5 Suppl High-Dose):S29-36. PubMed ID: 18662521
    [No Abstract]   [Full Text] [Related]  

  • 19. The lower the better? Experiences from cardiovascular disease and stroke prevention.
    Olsson AG
    Acta Neurol Scand Suppl; 2006; 185():58-62. PubMed ID: 16866912
    [No Abstract]   [Full Text] [Related]  

  • 20. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
    Mega JL; Morrow DA; Cannon CP; Murphy S; Cairns R; Ridker PM; Braunwald E
    J Thromb Thrombolysis; 2006 Aug; 22(1):71-6. PubMed ID: 16786236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.